Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

USA - NASDAQ:SRPT - US8036071004 - Common Stock

22.11 USD
-1.02 (-4.41%)
Last: 10/10/2025, 8:58:27 PM
21.58 USD
-0.53 (-2.4%)
After Hours: 10/10/2025, 8:58:27 PM
Fundamental Rating

3

Taking everything into account, SRPT scores 3 out of 10 in our fundamental rating. SRPT was compared to 536 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRPT had negative earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
SRPT had negative earnings in 4 of the past 5 years.
SRPT had negative operating cash flow in 4 of the past 5 years.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of -1.57%, SRPT belongs to the best of the industry, outperforming 88.99% of the companies in the same industry.
SRPT's Return On Equity of -4.27% is amongst the best of the industry. SRPT outperforms 90.49% of its industry peers.
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 79.28%, SRPT belongs to the top of the industry, outperforming 84.70% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of 0.17. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.17, SRPT is in line with its industry, outperforming 58.58% of the companies in the same industry.
SRPT has a Debt/Equity ratio of 0.84. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
The Debt to Equity ratio of SRPT (0.84) is worse than 74.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0.17
ROIC/WACCN/A
WACC8.39%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

SRPT has a Current Ratio of 2.89. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT has a worse Current ratio (2.89) than 64.93% of its industry peers.
A Quick Ratio of 1.81 indicates that SRPT should not have too much problems paying its short term obligations.
SRPT has a worse Quick ratio (1.81) than 76.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 1.81
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SRPT have decreased strongly by -293.33% in the last year.
The Revenue has grown by 64.89% in the past year. This is a very strong growth!
Measured over the past years, SRPT shows a very strong growth in Revenue. The Revenue has been growing by 37.94% on average per year.
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%

3.2 Future

The Earnings Per Share is expected to grow by 7.30% on average over the next years.
The Revenue is expected to decrease by -5.18% on average over the next years.
EPS Next Y-296.75%
EPS Next 2Y1.05%
EPS Next 3Y-4.56%
EPS Next 5Y7.3%
Revenue Next Year9.01%
Revenue Next 2Y-8.25%
Revenue Next 3Y-8.68%
Revenue Next 5Y-5.18%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 9.50, the valuation of SRPT can be described as very reasonable.
SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 97.57% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.57. SRPT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.5
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

90.67% of the companies in the same industry are more expensive than SRPT, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 61.54
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as SRPT's earnings are expected to decrease with -4.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.05%
EPS Next 3Y-4.56%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (10/10/2025, 8:58:27 PM)

After market: 21.58 -0.53 (-2.4%)

22.11

-1.02 (-4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners81.76%
Inst Owner Change0%
Ins Owners4.63%
Ins Owner Change11.51%
Market Cap2.31B
Analysts67.43
Price Target32.92 (48.89%)
Short Float %20.32%
Short Ratio1.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)-1.95%
PT rev (3m)-44.02%
EPS NQ rev (1m)-13.65%
EPS NQ rev (3m)-8320.9%
EPS NY rev (1m)5.93%
EPS NY rev (3m)-74.63%
Revenue NQ rev (1m)-5.69%
Revenue NQ rev (3m)-34.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.5
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.74
EV/EBITDA 61.54
EPS(TTM)-0.87
EYN/A
EPS(NY)2.33
Fwd EY10.53%
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-2.87
OCFYN/A
SpS23.71
BVpS12.97
TBVpS12.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.28%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA 28.38
Cap/Depr 372.98%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 1.81
Altman-Z 0.17
F-Score2
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-296.75%
EPS Next 2Y1.05%
EPS Next 3Y-4.56%
EPS Next 5Y7.3%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year9.01%
Revenue Next 2Y-8.25%
Revenue Next 3Y-8.68%
Revenue Next 5Y-5.18%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A